Viridian has its approval. Now it has to take patients from Amgen

The technology

Viridian makes antibodies against the IGF-1 receptor, the same target as Amgen's Tepezza, for thyroid eye disease (TED). The disease causes swelling behind the eyes that leads to bulging, double vision and pain. Lumvoa (veligrotug-vvze) was approved on June 26 for TED regardless of activity or duration. It is given as five 30 to 45 minute infusions, against eight longer ones for Tepezza.

Elegrobart is the follow-on: a half-life-extended antibody given under the skin. In REVEAL-2, in chronic TED, 50% and 54% of patients on four-week and eight-week dosing had a proptosis response at week 24, versus 15% on placebo. REVEAL-1 in active TED showed 54% and 63% versus 18%. Viridian plans an at-home autoinjector.

Beyond TED, the company has two FcRn inhibitors in early development, VRDN-006 and VRDN-008, and an anti-TSHR antibody aimed at TED and Graves' disease, with an IND planned in the fourth quarter.

The odds

Lumvoa's regulatory risk is gone. Elegrobart has two positive phase 3 trials and a BLA planned for the first quarter of 2027. Filed applications historically won approval 90.6% of the time across diseases in the BIO/Informa/QLS data. The open regulatory questions are the label details, such as whether both dosing schedules are approved.

The FcRn programs face the class base rates. Phase 1 programs reached phase 2 52.0% of the time in the same data, and VRDN-008 must show it improves on approved FcRn drugs such as efgartigimod, which Viridian used as its preclinical comparator.

The money

Cash, cash equivalents and marketable securities were $981.5 million at June 30. The company lost $127.1 million in the second quarter as selling costs rose to $55.0 million. In May it raised $394 million gross from stock and 1.75% convertible notes due 2032, and it repaid its Hercules loan, about $55.1 million that carried interest of at least 8.95%. The notes pay 1.75% and mature in 2032, and up to 14.7 million shares could be issued if they convert at the maximum rate. That is meaningful against 113.2 million common shares outstanding at June 30, but it is a cost the company chose over higher-rate debt.

Viridian says its cash plus expected Lumvoa and elegrobart revenue should fund it through profitability. It reported no product revenue in the second quarter because the drug was approved four days before quarter end.

The risks

Competition comes first. Tepezza had $1.9 billion in 2025 revenue, and Amgen is developing subcutaneous options. Viridian set Lumvoa's price in line with Tepezza, about $150,000 for a six-month course, so it has to win on convenience and data.

Safety is shared with the class. Hearing impairment occurred in 17% of Lumvoa patients versus 6% on placebo, and the label calls for hearing checks.

Supply is concentrated. Viridian relies on WuXi Biologics for commercial veligrotug, and its 10-Q warns that the BIOSECURE Act and similar measures could disrupt Chinese suppliers.

Our read

Viridian took an antibody through two phase 3 trials to approval and has a second product right behind it. The company's own plan rests on new chronic TED patients more than on switching Tepezza users, which is a bigger market but a slower one to build. The infusion and the injection could also compete with each other once elegrobart arrives. The cash removes funding pressure. The test is commercial, starting with third-quarter Lumvoa sales and the elegrobart filing in early 2027.